Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $4.91 -2.77%
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Research and development for proprietary programs: 46.56M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- INVO Fertility (IVF) Tops Q2 EPS by 105c
- Is Treasury selloff a major issue for stock market bulls?
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
